Want to see VERA full AI Analyst Report?

Vera Therapeutics (VERA) Price & Analysis

951 Followers

VERA Stock Chart & Stats

$35.28

$0.05(0.14%)

At close: Jul 27 4:00 PM EDT

$35.28

$0.05(0.14%)

Day’s Range― - ―

52-Week Range$23.05 - $56.05

Previous CloseN/A

Volume472.67K

Average Volume (3M)2.26M

Market Cap

$2.08B

Enterprise Value$2.66B

Total Cash (Recent Filing)$499.16M

Total Debt (Recent Filing)$75.23M

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Nov 05, 2026

EPS Estimate

-1.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.86

Shares Outstanding72,063,330

10 Day Avg. Volume1,988,082

30 Day Avg. Volume2,259,741

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)5.38

Price to Sales (P/S)0.00

P/FCF Ratio-13.46

Enterprise Value/Market Cap1.28

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-6.75

Forecast

1Y Price Target

$69.10

Price Target Upside95.86% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-6.24

Revenue Forecast (FY)$24.14M

Bulls Say, Bears Say

Bulls Say

Phase 3 Clinical EfficacyThe successful 428-patient Phase 3 trial provides substantial evidence that TRUTAKNA can slow IgA nephropathy progression, supported by kidney-function, proteinuria, and hematuria improvements. Durable efficacy and favorable safety can strengthen physician adoption and support longer-term commercial execution.

Regulatory And Commercial ProgressFDA accelerated approval materially advances Vera from a clinical-stage developer toward commercialization, while early patient start forms indicate initial treatment uptake. Together, these milestones improve the probability of building a revenue base and create a platform for broader autoimmune indications.

Modest Financial LeverageRelatively modest leverage reduces the immediate pressure from debt service while Vera funds commercialization and ongoing development. The remaining equity base provides some financial capacity and leaves solvency risk more connected to operating cash burn than to an already-heavy debt burden.

Bears Say

No Commercial RevenueThe absence of commercial revenue means Vera has not yet demonstrated a recurring sales engine or established margin structure. Future financial performance therefore remains highly dependent on converting regulatory progress into sustained prescriptions, payer support, and successful commercial execution.

Heavy Cash BurnLarge negative operating and free cash flow indicates that Vera currently consumes substantial capital to sustain operations rather than funding itself internally. Continued burn can require external financing, potentially limiting strategic flexibility and increasing dilution or funding pressure over the next several quarters.

Widening Losses And Shrinking EquityAccelerating losses and declining equity show that capital is being consumed before the business has established profitability. This weakens the balance-sheet cushion over time and raises the importance of achieving commercial scale quickly enough to offset development and launch expenses.

Vera Therapeutics News

Vera Therapeutics initiated with a Market Perform at Leerink

Leerink initiated coverage of Vera Therapeutics (VERA) with a Market Perform rating and $34 price target The firm...

9d ago

VERA

Vera Therapeutics price target lowered to $60 from $66 at BofA

BofA lowered the firm’s price target on Vera Therapeutics (VERA) to $60 from $66 and keeps a Buy...

12d ago

VERA

Vera Therapeutics announces ORIGIN 3 final efficacy analysis of Trutakna

Vera Therapeutics (VERA) announced that there will be multiple presentations at the American Society of Nephrology, ASN, Kidney...

19d ago

VERA

2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be Brewing

Should you short stocks right now? That’s a good question, and it’s one with no clear answer. There’s...

1M ago

VERA

WULF

Rami Katkhuda Reiterates Buy on Trutakna, Citing Strong Clinical and Early Commercial Traction; $90 Price Target Maintained

LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VERA stock, giving a Buy rating today....

1M ago

VERA

Vera Therapeutics ORIGIN 3 study results positive, says Raymond James

After Vera Therapeutics (VERA) reported the final efficacy analysis for their pivotal ORIGIN 3 study needed for full...

1M ago

VERA

Morning Movers: Vera Therapeutics surges after reporting IgAN study data

Stock futures are pointing to another lower open as investors brace for the Federal Reserve to begin its...

1M ago

FPS

LLY

Vera Therapeutics Reports Successful TRUTAKNA Phase 3 Results

Vera Therapeutics ( ($VERA) ) has shared an announcement. On September 15, 2026, Vera Therapeutics reported that TRUTAKNA...

1M ago

VERA

Vera Therapeutics up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data

07:05 EDT Vera Therapeutics (VERA) up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data Published first...

1M ago

VERA

Vera Therapeutics’ trutakna meets all efficacy endpoints in IgAN trial

Vera Therapeutics (VERA) announced that trutakna met all prespecified endpoints of the final efficacy analysis of the ORIGIN...

1M ago

VERA

Vera Therapeutics price target raised to $83 from $76 at JPMorgan

JPMorgan raised the firm’s price target on Vera Therapeutics (VERA) to $83 from $76 and keeps an Overweight...

1M ago

VERA

3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts

Analysts see strong momentum in some stocks this week, including Fervo Energy ($FRVO), Vera Therapeutics ($VERA), and Hut 8...

2M ago

HUT

FRVO

Buy Rating Reiterated on Vera as Atacicept Data Strengthens Case and Shares Trade Below Unchanged $66 Price Target

Vera Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on August 14. Analyst Dina...

2M ago

VERA

Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vera Therapeutics (VERA) to $90 from $125 and keeps a...

2M ago

VERA

VERA FAQ

What was Vera Therapeutics’s price range in the past 12 months?

Vera Therapeutics lowest stock price was $23.05 and its highest was $56.05 in the past 12 months.

What is Vera Therapeutics’s market cap?

Vera Therapeutics’s market cap is $2.08B.

When is Vera Therapeutics’s upcoming earnings report date?

Vera Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.

How were Vera Therapeutics’s earnings last quarter?

Vera Therapeutics released its earnings results on Aug 10, 2026. The company reported -$1.52 earnings per share for the quarter, beating the consensus estimate of -$1.576 by $0.056.

Is Vera Therapeutics overvalued?

According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vera Therapeutics pay dividends?

Vera Therapeutics does not currently pay dividends.

What is Vera Therapeutics’s EPS estimate?

Vera Therapeutics’s EPS estimate is -1.61.

How many shares outstanding does Vera Therapeutics have?

Vera Therapeutics has 72,063,330 shares outstanding.

What happened to Vera Therapeutics’s price movement after its last earnings report?

Vera Therapeutics reported an EPS of -$1.52 in its last earnings report, beating expectations of -$1.576. Following the earnings report the stock price went down -4.085%.

Which hedge fund is a major shareholder of Vera Therapeutics?

Currently, no hedge funds are holding shares in VERA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vera Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-84.13%

Trailing 12-Months

Asset Growth

-7.87%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Vera Therapeutics

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Vera Therapeutics (VERA) Earnings & Revenues

Historic Earnings Reports

VERA Stock 12 Month Forecast

Average Price Target

$69.10

▲(95.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","64":"$64","101":"$101","45.5":"$45.5","82.5":"$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,45.5,64,82.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.99,36.29846153846154,41.606923076923074,46.91538461538461,52.223846153846154,57.5323076923077,62.840769230769226,68.14923076923077,73.45769230769231,78.76615384615384,84.07461538461538,89.38307692307693,94.69153846153846,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.99,33.92153846153846,36.85307692307692,39.78461538461538,42.716153846153844,45.64769230769231,48.57923076923076,51.51076923076923,54.44230769230769,57.37384615384615,60.30538461538461,63.23692307692308,66.16846153846153,{"y":69.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.99,31.22153846153846,31.45307692307692,31.684615384615384,31.916153846153843,32.14769230769231,32.379230769230766,32.61076923076923,32.84230769230769,33.073846153846155,33.30538461538462,33.536923076923074,33.76846153846154,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.23,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.99,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >